Holen Sie sich die Stockscreener-App
16.54
5.55%
0.87
Vorhandelsmarkt:
16.32
-0.22
-1.33%
Atrium Therapeutics Inc Aktie (RNA) Neueste Nachrichten
Atrium Therapeutics Inc. share price - Capital.com
Trade Atrium Therapeutics Inc.RNA CFD - Capital.com
Atrium Tx launches with Avidity's RNA ticker and cardio assets - BioWorld MedTech
Atrium Therapeutics, Inc. (RNA): An Insightful Analysis of a Biotech Challenger with a $2.28 Billion Market Cap - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to NASDAQ Composite Index - marketscreener.com
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
RNA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Q4 Earnings Estimate for CVE:DWS Issued By Atrium Research - Defense World
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Finviz
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding - GuruFocus
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates - marketscreener.com
Atrium Therapeutics Launches with $270M - Contract Pharma
Novartis completes acquisition of Avidity Biosciences - TipRanks
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting - TipRanks
[POSASR] Avidity Biosciences, Inc. SEC Filing - Stock Titan
As Novartis deal closes, Avidity's rare heart disease spinout launches with $270M - Endpoints News
Novartis (NVS) Completes Acquisition of Avidity Biosciences - GuruFocus
Novartis Completes Acquisition of Avidity Biosciences - marketscreener.com
Novartis completes acquisition of Avidity Biosciences; shares to be delisted from Nasdaq - Investing.com
Novartis Closes $12 Billion Acquisition of Avidity Biosciences - marketscreener.com
Avidity Biosciences Ends ATM Sales Agreement With TD Securities Following Novartis Merger Close - TradingView
Avidity Biosciences Inc (RNAM-Q) Stock Price and News - The Globe and Mail
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies - PR Newswire
Novartis completes $12 billion Avidity Biosciences acquisition - Investing.com
Avidity Biosciences (RNA) taken private as Novartis merger closes, delisting set - Stock Titan
Why Is Avidity Biosciences Stock (RNA) Down Today? - TipRanks
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Avidity Biosciences (RNAM) Peg Ratio (TTM) - Zacks Investment Research
S&P 500 Futures Decline In Premarket Trading; Avidity Biosciences, Duolingo Lag - 富途牛牛
S&P 500 Futures Decline in Premarket Trading; Avidity Biosciences, Duolingo Lag - Barron's
Avidity Biosciences, Inc. $RNA Shares Bought by JPMorgan Chase & Co. - MarketBeat
Why Avidity Biosciences Shares Are Sliding Now - TipRanks
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - BioSpace
Avidity Shareholders Approve Novartis Merger and Spin-Off - TipRanks
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Avidity Biosciences (RNA) investors approve Novartis merger and Atrium spin-off - Stock Titan
One-year Duchenne study ties treatment to near-normal creatine kinase levels - Stock Titan
Cash from financing activities of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Promising Medical Stocks To Follow TodayFebruary 26th - MarketBeat
Promising Pharmaceutical Stocks To Follow NowFebruary 26th - MarketBeat
Avidity Biosciences, Inc. Cash Flow – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Balance Sheet – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Financial Statements – NASDAQ:RNAM - TradingView
Net income of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Revenue Breakdown – NASDAQ:RNAM - TradingView
A Look At Avidity Biosciences (RNA) Valuation After Strong Multi Year Shareholder Returns - simplywall.st
Avidity Biosciences, Inc.(NasdaqGM: RNAM) dropped from NASDAQ Biotechnology Index - marketscreener.com
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Bought by Vanguard Group Inc. - MarketBeat
Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives - simplywall.st
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):